Invesco — 2018 Investments
2 investments dated 2018 · listed companies and verified rows first · show all
Prothena is a clinical-stage biotechnology company developing investigational therapies for neurodegenerative and rare peripheral amyloid diseases by targeting misfolded proteins.
BiotechDun Laoghaire, Co. Dublin, US
Tran B. Nguyen(Executive Officer)Arthur W. Homan(Executive Officer)Karin L. Walker(Executive Officer)inTara Nickerson, Ph.D.(Executive Officer)Wagner M. Zago, Ph.D.(Executive Officer)Carol D. Karp(Executive Officer)in
Co-investorsSofinnova VenturesRA CapitalWellington Management
Advanced ManufacturingBothell, US
James Thompson(Executive Officer, Director)inCraig Crowell(Executive Officer, Director)in
BoardMassoud Entekhabi(Director)Alan Matthews(Director)Kent Johnson(Director)
Co-investorsConsensus Business GroupCredit Suisse
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.